07:00 , Aug 25, 2003 |  BC Week In Review  |  Company News

Nucleonics, Wyeth deal

Nucleonics received co-exclusive worldwide rights to WYE's patent applications covering the delivery into cells of DNA constructs expressing long or short interfering RNAs to silence the expression of specific genes. The applications are based on...
07:00 , Aug 20, 2003 |  BC Extra  |  Company News

Nucleonics, Wyeth RNAi deal

Nucleonics (Malvern, Penn.) received co-exclusive worldwide rights from Wyeth (WYE) to patent applications covering the delivery into cells of DNA constructs expressing long or short interfering RNAs to silence expression of specific genes. The applications...
08:00 , Mar 28, 2001 |  BC Extra  |  Company News

Zurawski appointed CEO of CGEN subsidiary

Vincent Zurawski, former director of research business development at the University of Pennsylvania (Philadelphia, Penn.), was appointed CEO of the U.S. subsidiary of functional genomics play Compugen (CGEN). Zuarwski previously co-founded Johnson & Johnson (JNJ)...
07:00 , Jun 8, 1998 |  BioCentury  |  Strategy

Transactions involving AHP & Monsanto

Transactions involving AHP & Monsanto Acquisitions Asgrow Agronomics Seeds Agracetus Agricultural biotechnology Agroceres Corn seeds (Brazil) Biopol Biodegradable plastics Calgene Agricultural biotechnology DeKalb Genetics Corn and soybean seeds (acquisition pending) Delta & Pine Land Cotton...
07:00 , May 18, 1998 |  BC Week In Review  |  Company News

Apollon, Wyeth-Lederle Vaccines deal

Wyeth-Lederle, a unit of Wyeth-Ayerst Laboratories , acquired Apollon, a developer of DNA-based vaccine technology. Terms of the deal were undisclosed. Apollon's Genevax vaccine is in Phase II trials for HSV and in Phase I...
08:00 , Dec 8, 1997 |  BC Week In Review  |  Company News

Apollon, Biogen deal

Apollon received a license to BGEN's DNA sequences that encode hepatitis B viral antigens. BGEN retains the right to grant a limited number of other licenses to the technology. BGEN will purchase 83,333 shares (assuming...
08:00 , Dec 8, 1997 |  BioCentury  |  Finance

Disgruntled

The Biotechnology Value Fund was to announce today that it is opposed to the proposed merger between Arris and Sequana . The fund holds a 5 percent stake in ARRS, according to fund manager Mark...
07:00 , Oct 20, 1997 |  BioCentury  |  Finance

Attention getting

Innogenetics has provided EASDAQ's detractors with evidence that traders can show up on the pan-European exchange. After stagnating for almost a year, INNX (Ghent, Belgium) burst into activity in the past two weeks, its share...
07:00 , Jul 21, 1997 |  BC Week In Review  |  Company News

Apollon, University of Pennsylvania other research news

Apollon and university researchers published in Nature Biotechnology the use of CD86 coexpression, along with plasmid DNA encoding for HIV-1 antigens, to stimulate cytotoxic T lymphocyte (CTL) induction. The technique could help optimize immune responses...
07:00 , May 5, 1997 |  BC Week In Review  |  Clinical News

Apollon preclinical data

Apollon announced that chimpanzees vaccinated with its product were protected from HIV infection. As reported in Nature Medicine, the two chimps received several doses of the vaccine. Both antibody and killer T cell responses were...